Murine models for antiretroviral therapy.
Rauscher murine leukemia virus (RLV) infection of adult mice results in splenomegaly that is proportional to the virus titer. We have used this model to study the therapy of chronic viremia as well as chemoprophylaxis after viral exposure, both with single agents and with combination therapy. We showed that prompt initiation of effective antiviral therapy after viral exposure can prevent de novo infection. We have also developed a murine neurotropic retrovirus model which allows analysis of candidate antiviral agents for activity across the blood-brain barrier. This model can also be used to study therapeutic approaches to retroviral infections acquired at midgestation or during the neonatal period.
Ruprecht
R M
RM
Dana-Farber Cancer Institute, Boston, Mass. 02115.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000818:Animals; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D007370:Interferon Type I / Q000627:therapeutic use; D009052:Leukemia Virus, Murine / Q000187:drug effects; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000517:prevention & control / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D011925:Rauscher Virus / Q000187:drug effects; D011994:Recombinant Proteins; D012190:Retroviridae / Q000187:drug effects; D012192:Retroviridae Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000628:therapy; D014766:Viremia / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D015215:Zidovudine / Q000627:therapeutic use*
D007370:Interferon Type I; D011994:Recombinant Proteins; D015215:Zidovudine